StockNews.AI
NRXS
StockNews.AI
210 days

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

1. NeurAxis secures insurance coverage for IB-Stim, expanding to 5.1 million members. 2. IB-Stim treats IBS pain in adolescents aged 8-21, filling a treatment gap. 3. Insurance coverage increased significantly, from 4 million to 51 million lives. 4. Expanded age range for IB-Stim treatment boosts potential market capacity significantly. 5. NeurAxis focuses on underserved pediatric and adult conditions with ongoing trials.

6m saved
Insight
Article

FAQ

Why Bullish?

The expansion of insurance coverage suggests increased potential revenue for NRXS. Historical examples show similar coverage expansions leading to stock price gains.

How important is it?

The article highlights critical milestones for NRXS's business strategy related to market expansion. Increased insurance coverage directly influences future revenue streams and stock performance.

Why Long Term?

As insurance coverage expands, NRXS may see sustained growth over time. Long-term revenue from increased market access enhances company valuation.

Related Companies

IB-StimN/A
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states. NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy. Brian Carrico, President and Chief Executive Officer of NeurAxis, commented, "We are thrilled about our recent insurance coverage, which marks our initial expansion into the states of MI, IL, NY, TX, and others. This milestone underscores the impact of our strong body of published research, which continues to drive broader insurance coverage for IB-Stim. As highlighted in my recent Letter to Shareholders, we've significantly increased our insurance coverage to 51 million lives—a remarkable leap from just 4 million a year ago. Additionally, our recently achieved CPT I code, and the expanded age range from 11–18 years to 8–21 years will allow us to provide care for the approximately 600,000 individuals suffering from irritable bowel syndrome." About NeurAxis, Inc. NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. For Important Information on IB-Stim/PENFS: See https://ibstim.com/important-information/ Contacts: CompanyNeurAxis, Inc.info@neuraxis.com   Investor Relations Lytham PartnersBen Shamsian646-829-9701shamsian@lythampartners.com

Related News